|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis显示文摘AIM: To investigate the antif ibrotic effects of peginterferon- alpha 2b and taurine on oxidative stress markers and hepatocellular apoptosis. METHODS: Sixty rats with CCl4-induced liver fibrosis were divided into 4 groups (n = 15). Group 1 was left for spontaneous recovery (SR). Groups 2-4 received peginterferon-alpha 2b, taurine, and their combination, respectively, for four weeks. Histological f ibrosis scores, histomorphometric analysis, tissue hydroxyproline, tissue MDA, GPx and SOD activities were determined. Activated stellate cells and hepatocellular apoptosis were also evaluated. RESULTS: The degree of f ibrosis decreased in all treatment groups compared to spontaneous recovery group. Taurine alone and in combination with peginterferon-alpha 2b reduced oxidative stress markers, but peginterferon-alpha 2b alone did not. Apoptotic hepatocytes and activated stellate cells were higher in groups 2-4 than in group 1. Combined taurine and peginterferon-alpha 2b further reduced fibrosis and increased activated stellate cell apoptosis, but could not improve oxidative stress more than taurine alone.CONCLUSION: Peginterferon-alpha 2b exerts anti- f ibrotic effects on rat liver fibrosis. It seems ineffective against oxidative stress in vivo. Peginterferon-alpha 2b in combination with taurine seems to be an antif ibrotic strategy. | Ilker Tasci Mehmet Refik Mas Sevil Atalay Vural Salih Deveci Bilgin Comert Gunay Alcigir Nuket Mas Cemal Akay Mithat Bozdayi Cihan Yurdaydin Hakan Bozkaya Ozden Uzunalimoglu Ahmet Turan Isik Harun M Said | 2007 | World Journal of Gastroenterology2007，13，23： | 7 |
| 2 | Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐na?ve patients with HBV‐related decompensated cirrhosis显示文摘 | H. L.Y. Chan Y. C. Chen E. J. Gane S. K. Sarin D. J. Suh T. Piratvisuth B. Prabhakar S. G. Hwang G. Choudhuri R. Safadi T. Tanwandee A. Chutaputti C. Yurdaydin W. Bao C. Avila A. Trylesinski | 2012 | Journal of Viral Hepatitis2012，，10： | 3 |
| 3 | Treatment of Chronic Delta Hepatitis显示文摘 | Cihan Yurdaydin | 2012 | Semin Liver Dis2012，，03： | 2 |
| 4 | Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a显示文摘 | Patrick Marcellin Ferruccio Bonino George K.K. Lau Patrizia Farci Cihan Yurdaydin Teerha Piratvisuth Rui Jin Selim Gurel Zhi-Meng Lu Jian Wu Matei Popescu Stephanos Hadziyannis | 2009 | Gastroenterology2009，，7： | 2 |
| 5 | Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a显示文摘 | Patrick Marcellin Ferruccio Bonino George K.K. Lau Patrizia Farci Cihan Yurdaydin Teerha Piratvisuth Rui Jin Selim Gurel Zhi-Meng Lu Jian Wu Matei Popescu Stephanos Hadziyannis | 2009 | Gastroenterology2009，，7： | 1 |
| 6 | Hepatic Encephalopathy显示文摘 | Yurdaydin C Idilman R | 2012 | European Gastroenterology&Hepatology Review2012，7，4： | 1 |
| 7 | Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, bio- chemical, and serology outcomes through 96 weeks 显示文摘 | Sherman M Yurdaydin C Simsek H | 2008 | Hepatology2008，48，1： | 1 |
| 8 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 9 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir显示文摘 | George V. Papatheodoridis George N. Dalekos Cihan Yurdaydin Maria Buti John Goulis Pauline Arends Vana Sypsa Spilios Manolakopoulos Giampaolo Mangia Nikolaos Gatselis Onur Kesk?n Savvoula Savvidou Bettina E. Hansen Christos Papaioannou Kostantinos Galanis | 2014 | Journal of Hepatology2014，，： | 1 |
| 10 | On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment, subsequent I-IBsAg clearance in HBeAg-negative hepatitis B virus- infected patients treated with peginterferon alfa-2a 显示文摘 | Marcellin P Piratvisuth T Brunetto M Bonino F Farci P Yurdaydin C Gurel S Kapprell HP Messinger D Popescu M | 2010 | Hepatol Int2010，4，： | 1 |
| 11 | Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 显示文摘 | Brunetto MR Moriconi F Bonino F Lau GK Farci 19 Yurdaydin C Piratvisuth T Luo K Wang Y Hadziyannis S Wolf E McCloud P Batrla R Marcellin P | 2009 | Hepatology2009，49，4： | 1 |
| 12 | Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine显示文摘 | Bozkaya H Yurdaydin C T rtiner M | 2002 | Dig Dis Sci2002，47，8： | 1 |
| 13 | Budd-Chiari syndrome with multislice contrast enhanced three dimentional MR angiography显示文摘 | Erden A Karayalcin S Yurdaydin C | 2002 | ARJ2002，179，5： | 1 |
| 14 | Entecavir for treatment of lamivudine-refractory, HBeAg positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 15 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 16 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 17 | Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks显示文摘 | Sherman M Yurdaydin C Simsek H | 2008 | Hepatology2008，45，1： | 1 |
| 18 | Cytotoxic CD4 T cells in viral hepatitis显示文摘 | Aslan N Yurdaydin C Wiegand J | 2006 | J Viral Hepat2006，13，8： | 1 |
| 19 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | | 0，，07： | 1 |
| 20 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员